Skip to Main Content

Skip Nav Destination

Article navigation

CCR Translations| February 14 2023

Viewing RCC with a DNA Methylation Lens ENHANCES Understanding of ICI Resistance

Mi Zhou

0000-0001-8144-3468

;

Mi Zhou

1Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina.

Search for other works by this author on:

PubMed

Google Scholar

William Y. Kim

0000-0001-7922-2156

William Y. Kim *

1Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina.

2Department of Medicine, Division of Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.

3Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.

4Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.

*Corresponding Author: William Y. Kim, Lineberger Comprehensive Cancer Center, University of North Carolina, CB# 7295, 450 West Drive, Chapel Hill, NC 27599-7295. Phone: 919-966-4765; Fax: 919-966-8212; E-mail: wykim@med.unc.edu

Search for other works by this author on:

PubMed

Google Scholar

Author & Article Information

*Corresponding Author: William Y. Kim, Lineberger Comprehensive Cancer Center, University of North Carolina, CB# 7295, 450 West Drive, Chapel Hill, NC 27599-7295. Phone: 919-966-4765; Fax: 919-966-8212; E-mail: wykim@med.unc.edu

Clin Cancer Res 2023;29:1–3

Received: December 06 2022

Revision Received: January 04 2023

Accepted: January 13 2023

Online Issn: 1557-3265

Print Issn: 1078-0432

©2023 American Association for Cancer Research

2023

American Association for Cancer Research

Clin Cancer Res OF1–OF3.

https://doi.org/10.1158/1078-0432.CCR-22-3574

Summary

Clear-cell renal cell carcinoma tumors with an enhancer demethylator phenotype (TED) harbor a worse prognosis and derive less clinical benefit from immunotherapy. The TED phenotype may help predict immunotherapy resistance.

See related article by XXXX et al., p. 000

This content is only available via PDF.

©2023 American Association for Cancer Research

2023

American Association for Cancer Research

You do not currently have access to this content.

Don't already have an account? Register

You could not be signed in. Please check your email address / username and password and try again.